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Abstract 
Photochemical internalisation (PCI) is a site-specific technique for improving cellular delivery of 
macromolecular drugs. In this study, a cell penetrating peptide, containing the core HIV-1 Tat 48­
57 sequence, conjugated with a porphyrin photosensitiser has been shown to be effective for PCI. 
Herein we report an investigation of the photophysical and photobiological properties of a water 
soluble bioconjugate of the cationic Tat peptide with a hydrophobic tetraphenylporphyrin 
derivative. The cellular uptake and localisation of the amphiphilic bioconjugate was examined in 
the HN5 human head and neck squamous cell carcinoma cell line. Efficient cellular uptake and 
localisation in endo/lysosomal vesicles was found using fluorescence detection, and light-
induced,rupture of the vesicles resulting in a more diffuse intracellular fluorescence distribution 
was observed. Conjugation of the Tat sequence with a hydrophobic porphyrin thus enables 
cellular delivery of an amphiphilic photosensitiser which can then localise in endo/lysosomal 
membranes, as required for effective PCI treatment. PCI efficacy was tested in combination with a 
protein toxin, saporin, and a significant reduction in cell viability was measured versus saporin or 
photosensitiser treatment alone. This study demonstrates that the cell penetrating peptide­
photosensitiser bioconjugation strategy is a promising and versatile approach for enhancing the 
therapeutic potential of bioactive agents through photochemical internalisation. 
Key words: Cell penetrating peptide, Tat peptide, Photodynamic Therapy, PDT, Photochemical 
Internalisation, PCI 
1. Introduction 
Photochemical Internalisation (PCI) is a technology developed by Berg and co-workers [1­
3], which can enhance drug delivery using light in combination with photosensitisers localised in 
endo/lysosomal membranes. The technique is aimed at improving the delivery of bioactive agents 
which become sequestered within endo/lysosomal vesicles and are therefore unable to exert their 
action upon the target site. With PCI, the light-induced rupture of the photosensitised vesicle 
membranes enables the agents to reach their intracellular target. The aim of this study was to 
investigate whether a cell penetrating peptide bioconjugate can be used to enhance drug delivery. 
Pharmaceutical agents can suffer from low bioavailability due either to poor cell 
membrane penetration and/or the lack of water solubility. In tackling this key problem in drug 
delivery, an active area of research to improving bioavailability is the conjugation of drugs with 
cell penetrating peptides (CPP), which can enhance the water solubility and cellular uptake of 
drugs [4]. Two studies independently reported the cell membrane translocation ability of the trans-
activating transcriptional activator (Tat), a protein from human immunodeficiency virus type I 
(HIV-1) [5,6] using the 86-mer Tat or the purified Tat protein. Both Tat proteins were able to 
enter cultured cells and induce the trans-activation of the viral promoter. The full-length protein 
was soon characterized as a protein with multiple functional domains [7,8] and the highly basic 
region which contains six arginine and two lysine in nine residues is assigned to the protein 
translocation activity [9]. Since then, other natural or designed proteins or peptides have also 
demonstrated the property of translocation [10]. These proteins and peptides all contain the highly 
positive charged protein transduction domains (PTDs) or cell penetrating peptides (CPPs) that are 
responsible for protein transduction, i.e. the translocation process across the cell membrane. 
Several approaches to linking pharmaceutical cargos to Tat peptides or other CPPs to 
overcome the cell membrane barrier have been carried out. To date, Tat peptides have been 
proven to facilitate the cell entry of various molecules ranging from peptides [11] with molecular 
weights of hundreds of Dalton to larger structures such as liposomes [12]. The remarkable success 
of Tat peptides in drug delivery has drawn considerable attention to the mechanisms involved in 
the internalisation and intracellular delivery. A reduction of cellular uptake was found when Tat 
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peptides were modified with single deletion or substitution of the core sequence 
‘GRKKRRQRRR’ in the basic domain resulted in the change of charges [13,14]. Diminished 
cellular uptake indicated the unique highly cationic nature of Tat peptides certainly plays a key 
role in the cell uptake process, and the direct electrostatic interaction between the positively 
charged Tat peptides and the negatively charged proteoglycans or glycosaminoglycans on the cell 
surface is believed to be required in the internalisation mechanism[15,16]. 
Despite earlier misinterpretations of the uptake mechanism resulting from artefacts caused 
during the cell fixation procedures, endocytic uptake is the generally recognised mechanism for 
Tat peptide and most other CPP mediated drug delivery [17,18]. Both lipid raft-mediated caveolar 
endocytosis and the clathrin-mediated endocytosis have been identified as endocytic routes of Tat-
fusion proteins [19,20], in addition to macropinocytosis, a rapid non-specific lipid raft cell uptake 
pathway [21]. To date, more than 20 Tat-derived short peptides with various modifications at 
either the N-terminal or the C-terminal ends have been used for delivering drugs into cells [22]. 
The advantages and versatility of the Tat peptide-mediated drug delivery have also been applied 
in vivo. For example, in a study conducted by Schwarze et al used a Tat fusion protein (120kD) in 
which β-galactosidase (116 kD) was ligated to the protein transduction domain [23]. After 
intraperitoneal injection in mice, the conjugate was found to distribute into virtually every organ 
and even cross the blood brain barrier after 4 hr. These promising results have led to the 
possibility of Tat peptides being used for in vivo drug delivery. 
Porphyrins and their analogues constitute the major class of photosensitising agents in 
photodynamic therapy (PDT), which is a local treatment for both malignant and no-malignant 
pathologies. Its therapeutic effects arise from the photo-oxidative damage initiated by the 
photosensitised generation of reactive oxygen species. [24]. As with other pharmaceutical agents, 
many photosensitising agents exhibit poor bioavailability being either too hydrophilic or 
conversely too hydrophobic and limited water solubility. Conjugation strategies that modify 
photosensitisers by linking to certain peptides or proteins with targeting function have been used 
to improve the selectivity of photosensitiser delivery [25,26]. For example, penetratin coupled to 
5-aminolevulinic acid was shown to be taken up by cells and could be successfully converted to 
photoporphyrin IX via the haem biosynthetic pathway [27]. CPP-porphyrin conjugates have been 
recently synthesized as photoactive compounds. Sibrian-Vazquenz et al synthesized different 
porphyrin-peptide conjugates bearing PEG linkers to several targeting sequences including the Tat 
peptide (48-60) to compare their cellular uptake, subcellular localisation and the phototoxicity in 
vitro [28]. Sehgal et al, from the same group, examined the cellular uptake and phototoxicity of 
five porphyrin-peptide conjugates using a prostate cancer cell line [29]. Recently we have also 
shown that a Tat-porphyrin conjugate is effective for antimicrobial PDT [30]. 
In photochemical internalisation (PCI), the light-induced rupture of the endo/lysosomal 
membranes enables therapeutic agents sequestered within endo/lysosomes to reach their 
intracellular target. In contrast to photodynamic therapy, PCI is a site-specific drug delivery 
technique where the therapeutic action is exerted by the drug itself but not the by photosensitiser 
or the reactive oxygen species. For example, previous studies in our laboratory have demonstrated 
successful reversal of doxorubicin drug resistance in vitro by PCI [31,32]. Other agents 
successfully delivered using PCI include siRNA [2] and a peptide nucleic acid (PNA), where the 
PNA was conjugated to a cell penetrating peptide but not the photosensitiser [33]. 
Using an in vivo rat liver model, we have also demonstrated that PCI-mediated release of 
low doses of a protein toxin can give enhanced tissue damage [1]. Type I ribosome inactivating 
proteins (RIPs) such as gelonin and saporin exert a lethal effect on protein synthesis only if 
delivered into the cytosol, however due to their size they can become sequestered within 
endo/lysosomes [34]. Enhanced drug delivery of saporin and other RIPs (gelonin) to the cytosol 
has previously been demonstrated using PCI technology and amphiphilic disulfonated 
photosensitisers in vitro [35-37]. These amphiphilic disulfonated photosensitisers were selected 
since they exhibit preferential localisation in endo/lysosomal membranes in order to promote the 
PCI effect. It is important to note that the criteria for selection of a photosensitiser for PCI are 
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distinct from PDT where localisation in several subcellular compartments may confer an 
advantage (e.g. in mitochondria) rather than the specific endo/lysosomal localisation required for 
PCI. Identification and optimisation of new photosensitising compounds for PCI therefore 
presents a different experimental challenge. 
In the present study, we investigated the hypothesis that a Tat-TPP conjugate could be 
particularly suitable for PCI because of the resulting amphiphilicity conferred by cationic Tat 
peptide sequence and the hydrophobic porphyrin. Such an amphiphilic structure should favour 
membrane binding essential for PCI, but retain good water solubility. Photophysical and 
biological studies of a peptide-porphyrin conjugate were carried out to assess its efficacy for PCI 
in enhancing intracellular delivery and cytotoxicity of the macromolecular toxin, saporin. 
2. Materials and Methods 
2.1. Chemicals 
Chemical reagents were purchased from Sigma-Aldrich (Gillingham, UK), Fluka (Gillingham, 
UK), Acros (Loughborough, UK), Lancaster (Lancashire, UK) and Novabiochem (Nottingham, 
UK). All other solvents were purchased from Fisher Scientific (Loughborough, UK) and used as 
received. Peptide grade dimethylformamide was purchased from Rathburn Chemicals Ltd. 
(Walkerburn, UK). Preparative RP-HPLC was performed on a Dionex HPLC system (Leeds, UK) 
consisting of an Ultimate 3000 WPS autosampler, a P680 preparative pump (HPG), a UVD 170U 
multiwavelength detector, and a Foxy Jr fraction collector. The purifications were performed on a 
Phenomenex Gemini 5 �m C-18 (250 x 30 mm) column with a flow rate of 22.5 mL/min. Mobile 
phase A was 0.1% TFA in water, mobile phase B was 0.1% TFA in acetonitrile. High resolution 
mass spectrometry was performed using a Bruker MicroTOF autospec ESI mass spectrometer 
(Coventry, UK). TPPS4 (tetrasulfonated tetraphenylporphine) was supplied by Frontier Scientific 
(Frontier Scientific Europe, Lancashire, UK). TPPS2a (disulfonated tetraphenylporphine) was a 
gift from PCI Biotech (Oslo, Norway). 
2.2. Synthesis of Tat-TPP conjugate 
The Tat-TPP conjugate 2 was prepared by the ligation of the maleoylporphyrin derivative 1 (5 eq) 
to a HIV-1 Tat 48-57 analogue (1 eq), wherein the peptide was extended at the C-terminus by the 
tetrapeptide amide GYKC-NH2 (Fig.1), as used elsewhere [38]. The peptide was synthesised by 9­
fluorenylmethoxycarbonyl (Fmoc)-SPPS, and the ligation reaction was performed in solution in 
DMSO containing pyridine, shielded from light, as recently described by us [30]. The crude 
product was isolated on a Discovery DSC-18 solid phase extraction cartridge (Supelco, 
Gillingham, UK). The desired compound was eluted with (5% MeCN-0.1% aq TFA) mobile 
phase: and lyophilised. 2 was subsequently characterised by high resolution mass spectrometry, 
and its purity confirmed as > 95% by analytical RP-HPLC. The Molecular Weight of the 
conjugate is 3869 Da. 
2.3. Cell line and cultivation 
The experiments in this study were carried out using HN5 human squamous cell carcinoma cells. 
HN5 cells were obtained from Prof. Michael O’Hare (UCL Dept. of Surgery and Ludwig Institute 
for Cancer Research, London, UK). Cells were cultured in Dulbecco’s Modified Eagle’s medium 
containing 10% FBS (Sigma-Aldrich, Gillingham, UK), 100�M nonessential amino acid, 2mM 
glutamine (Gibco BRL, Life Technologies Ltd, Paisley, UK) and 500�g/ml Gentamicin (Gibco 
BRL, Life Technologies Ltd, Paisley, UK). Cells were incubated at 37 °C in a humidified 
atmosphere containing 5% CO2. 
2.4. Preparation of Tat-TPP conjugate solutions in liposomes 
In order to demonstrate that the Tat-TPP conjugate is capable of portioning to lipid membranes, 
spectroscopic studies were carried out by mixing an aqueous solution of the conjugate with an 
aqueous dispersion of liposomes. Stock solutions of the Tat-TPP conjugate were prepared by 
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dissolving the powder in water at a concentration of 100 �M. The aqueous dispersions of DMPC 
(dimyristoyl phosphatidylcholine, Sigma-Aldrich, Gillingham, UK) liposomes were prepared 
according to the procedure described by Hope et al. [39]. A film of lipid (total 20 � moles) was 
prepared on the inside wall of a round bottom flask by evaporation of CHCl3 solutions containing 
the required amount of DMPC to obtain the molar percentage mixture. The obtained films were 
stored in a dessicator overnight under partial evacuation and were then admixed with 1 ml of PBS 
buffer solution in order to obtain lipid dispersions (12.5 mM). The solutions were vortex-mixed 
and then freeze-thawed six times from liquid nitrogen to 313 K (40 ºC). Dispersions were then 
extruded (10 times) through a 100 nm polycarbonate membrane (Whatman Nuclepore, Maidstone, 
UK). The extrusions were carried out at 307 K (34 ºC), well above the transition temperature of 
DMPC (297.2 K), using a 2.5 ml extruder (Lipex Biomembranes Inc., Vancouver, Canada). 
2.4.1. Photophysical Characterisation 
Absorption spectra were measured using a Perkin-Elmer Lambda 25 UV/Vis spectrometer 
(Perkin-Elmer, Beaconsfield, UK) with quartz cuvettes. Spectra were measured with samples 
prepared from the stock solution using different solvents, e.g. water, methanol, or deuterated 
methanol (CH3OD) (Sigma-Aldrich, Gillingham, UK). The fluorescence emission and excitation 
spectra of the conjugate in aqueous and liposomal solutions were measured using a LS50B 
Perkin-Elmer spectrofluorimeter (Perkin-Elmer, Beaconsfield, UK). A front surface 
excitation/detection geometric configuration was used to minimise self-absorption artefacts. 
2.4.2. Fluorescence lifetime measurements 
Fluorescence lifetimes were measured using the time-correlated single photon counting method 
(TCSPC). Dilute solutions in methanol at a concentration of 0.5 �M were employed. The light 
source was a 405 nm pulsed laser diode (EPL-405, Edinburgh Instruments Ltd., Livingston, UK) 
with a pulse duration of 90 picoseconds, and 5MHz repetition rate. The fluorescence was detected 
using a fast multialkali photomultiplier module (model H5773-04, Hamamatsu Photonics UK Ltd, 
Hertfordshire, UK) via a longpass filter (OG510, Schott, Stafford, UK) and a monochromator 
(model M300, Bentham Instrument Ltd, Berkshire, UK). TCSPC was carried out using a PC-
mounted board (TimeHarp100, PicoQuant GmbH, Berlin, Germany) and lifetimes were derived 
using FluoFit software (PicoQuant GmbH, Berlin, Germany). The Instrument Response Function 
®
(IRF) was obtained from a non-fluorescent scattering Ludox solution (Sigmal-Aldrich, 
Gillingham, UK). Optimum fitting with minimisation of the residuals was confirmed using a Chi­
2
squared value χ < 1.4. 
2.4.2. Singlet oxygen yield measurements 
The singlet oxygen phosphorescence at 1270 nm was detected using time-resolved photon 
counting from aerated solutions in deuterated methanol (CH3OD) in quartz cuvettes. For detection 
in the near-IR, a thermoelectrically cooled photomultiplier (model H10330-45, Hamamatsu 
Photonics Ltd, Hertfordshire, UK) was used, and emission was collected via a series of lenses 
from the cuvette in combination with a long-pass and a band-pass filter centred at 1270 nm 
(Infrared Engineering Ltd, Essex, UK). The solutions were excited using a 532 Nd:YAG laser 
(Lumanova GmbH, Hannover, Germany) with the beam axis aligned orthogonally to the 
collection optics. The laser was pulsed at a repetition rate of 3 kHz and a pulse length of 3 ns, 
giving a mean power of 8mW, and a fast photodiode (1 ns rise time, Becker-Hickl, Berlin, 
Germany) was used to synchronize the laser pulse with the photon counting detection system. A 
series of neutral density filters was used to attenuate the laser power. The photon counting 
equipment consisted of a PC-mounted multiscaler board (model MSA-300, Becker-Hickl, Berlin, 
Germany) and a pre-amplifier (Becker-Hickl, Berlin, Germany) which gave a resolution of 5 ns 
per channel. Time-resolved phosphorescence measurements were accumulated by the multiscaler 
board. The traces were analysed using FluoFit software (PicoQuant GmbH, Berlin, Germany) to 
extract the singlet oxygen decay lifetime. To calculate the quantum yield the standard zero-time 
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intercept analysis was used. TPPS4 (tetrasulfonated tetraphenylporphine) was chosen as the 
reference compound [40,41]. 
2.5. Cellular uptake of Tat-TPP 
4
HN5 cells were seeded in 96-well plates at 2.5x10 cells/well one day before drug application. For 
the time-dependent cell uptake experiment, cells were treated with 1�M Tat-TPP added from an 
aqueous stock solution for various time periods up to 8 hr. For temperature-dependent 
experiments, all protocols were the same except that the incubations of photosensitisers were 
performed at 4 ºC or 37 ºC for 1 hr. For the dose-dependent uptake measurement, cells were 
incubated with Tat-TPP with different concentrations from 0.1 �M to 5 �M for 18 hr. 
Comparative studies were carried out following the same protocols with 1 �g/ml (1.3 �M) TPPS2a 
instead. At the selected uptake measurement time points, cells were washed with PBS and 
incubated in clear DMEM medium (no phenol red; no serum) for fluorescence measurement using 
a spectrofluorimeter with a fibre-optic attachment designed to record fluorescence from 96 well 
plates (LS50B spectrofluorimeter, Perkin-Elmer, Beaconsfield, UK). 
2.6. Subcellular distribution, post-light redistribution and co-localisation studies using confocal 
microscopy 
HN5 cells were seeded overnight in Petri dishes incorporating a coverslip window on the 
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underside designed for microscopy (FluoroDish , World Precision Instruments, Stevenage, UK) 
and were then incubated with 2.5 �M Tat-TPP for 18 hr. After being thoroughly washed and 
incubated with fresh full medium for further 4 hr, cells were incubated with clear phenol red-free 
DMEM for fluorescence microscopy. The cellular distribution and redistribution after 10min light 
irradiation were observed by confocal microscopy (FluoView FV1000, 60x magnification, NA 
1.20, Olympus UK Ltd, Essex, UK). The light treatment was carried out on stage by using the 543 
nm laser of the microscope. Fluorescence images were taken during the irradiation process at 
several time points. For co-localisation studies, after the 18 hr incubation with the Tat-TPP 
conjugate (2.5 �M), and thrice washing and a further 4 hr incubation with fresh medium, cells 
were incubated for 30 min with 50 nM LysoTracker Green for lysosomal labelling or MitoTracker 
Green (Molecular Probes, Paisley, UK) for mitochondrial labelling. Clear medium was again used 
for live cell imaging using confocal microscopy. 
2.7. Phototoxicity of Tat-TPP and its PCI effect in combination with saporin 
HN5 cells were seeded at 5000 cells/well in 96-well plates overnight. Cells were treated with the 
Tat-TPP conjugate (0.05, 0.1 and 0.2 �M) or saporin (Sigma-Aldrich Gillingham, UK) (10, 25 nM) 
for 18 hr separately. Another three groups of cells were co-incubated with saporin (10, 25 or 
50nM) and 0.1�M Tat-TPP. Cells were then washed thrice with PBS and incubated a further 4 hr 
®
with fresh full medium. Irradiation was carried out for up to 5 min using a blue LumiSource
-2 
flatbed lamp with peak emission c. 420 nm and 7 mW cm output (PCI Biotech, Oslo, Norway). 
Cell viability was determined by means of the standard MTT (3-(4,5-dimethylthiazol-2-yl)-2,5­
diphenyltetrazolium bromide) (Sigma-Aldrich, Gillingham, UK) assay 2 days after the light 
exposure. 
2.8. Statistical analysis 
Results are presented as mean ± standard deviation (SD). Significant differences were assessed by 
two-tailed Student’s t-test analysis. p ≤ 0.05 was considered statistically significant. 
3. Results 
3.1. Spectroscopic studies 
The structure of the peptide-porphyrin conjugate is shown in Fig. 1. The lipophilic tetraphenyl 
porphyrin is coupled via a linker to the Tat peptide, which is cationically charged since the 
peptide contains several amino groups which will be protonated at physiological pH. The peptide 
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comprises the core HIV-1 Tat 48-57 sequence, with a C-terminal tetrapeptide extension 
containing cysteine, as described by Santra et al [38], to allow attachment of a functionalised 
porphyrin by bioorthogonal thiol-maleimide ligation (see Section 2.2). 
With this amphiphilic structure, the bioconjugate should in principle localise well in membranes 
with the hydrophobic porphyrin localised within the lipid membrane and the cationic Tat 
sequence residing at the anionic membrane surface. Based on this reasoning it was hypothesized 
that this bioconjugate would be effective for PCI. 
Fig. 1. Structures of modified tetraphenylporphyrin 1 and Tat-tetraphenylporphyrin (Tat-TPP) 
bioconjugate 2. 
3.2. Spectroscopic analysis of Tat-TPP 
Fig. 2 shows the absorbance spectrum of 5 �M Tat-TPP conjugate in aqueous solution (distilled 
water). The peak absorption of the Soret band was observed at 418 nm. The weaker series of Q 
band absorption peaks are shown in the inset with the longest wavelength peak in the red at 642 
nm (Fig. 2, inset). In methanol, the peak absorption was observed at 414 nm. At this wavelength, 
5 -1 -1 
the molar extinction coefficient was measured as 2.9 x 10 M cm in methanol. 
Fig. 2. Absorption spectrum of 5 �M Tat-TPP conjugate in aqueous solution. Inset: the Q band 
region from 450 nm to 700 nm. 
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The fluorescence emission and excitation spectra of the Tat-TPP conjugate in aqueous and DMPC 
liposomal solutions are shown in Fig. 3. Peak fluorescence emission in aqueous solution was 
detected at 652 nm and 714 nm, and the maximum excitation intensity was at 417 nm (λemission 651 
nm). Red-shifted fluorescence spectra were observed in the liposomal solution with peak 
fluorescence emission detected at 655 nm and 721 nm while the maximum excitation intensity 
was recorded at 420 nm. 
Fig. 3. Fluorescence spectrum of 2.5 �M Tat-TPP in aqueous and DMPC liposomal solutions. A: 
Emission spectra (λexcitation 420 nm); B: Excitation spectra (λemission 651 nm). The emission spectra 
were corrected for the variation of detector sensitivity with wavelength. Front surface 
excitation/detection geometry was employed to minimise self-absorption. 
3.3 Photophysical studies 
In order to minimise dimerisation due to the hydrophobic TPP moiety in the conjugate, methanol 
was chosen as the solvent for the fluorescence lifetime measurement. For the determination of the 
singlet oxygen quantum yield, deuterated methanol (CH3OD) was used. To confirm that the 
methanolic solutions at the concentrations studied were monomeric, absorption spectra were 
recorded as a function of concentration. It was necessary to check for the presence of any 
aggregation because aggregated porphyrins exhibit shorter fluorescence lifetimes and lower 
singlet oxygen quantum yields. The absorption spectra of the Tat-TPP conjugate were measured 
in methanol and deuterated methanol and the peak absorbance of the Soret Band (at 414 nm) was 
found to be linear versus concentration up to 2 �M confirming that Tat-TPP conjugate was present 
in monomeric form. 
3.3.1. Fluorescence lifetime measurements 
The measurement of the fluorescence lifetime of Tat-TPP in methanol (0.5 �M) exhibited a good 
mono-exponential decay fitting with the value of 8.7 ns (Table 1). A slightly longer value was 
observed in deuterated methanol (10.7 ns) as expected due to the isotope effect. For comparison, 
the lifetime of TPPS4 was measured as 9.7 ns in methanol. 
3.3.2. Singlet oxygen quantum yield 
The quantum yield of the Tat-TPP conjugate was measured in comparison with that of a known 
reference compound, TPPS4 (Φ� = 0.7 in CH3OD) [40,41]. Using standard zero-point intercept 
analysis with optically matched solutions [42], the singlet oxygen quantum yield of Tat-TPP was 
calculated as 0.54. 
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Table 1 summarizes the photophysical properties of the Tat-TPP conjugate. 

dH2O
a 
MeOH
b 
DMPC
c 
MeOD
d 
λabs Soret (nm) 418 414 - -
λabs Q (nm) 642 645 - ­
λex (nm) 417 - 420 ­
λem (nm) 652, 714 - 655, 721 ­
τF (ns) - 8.7 - 10.7 
- - - 0.54Φ� 
Table 1 A summary of the photophysical properties of the Tat-TPP conjugate. λabs Soret: the peak 
Soret band absorption; λabs Q: the peak Q band absorption in the red spectral region; λex: the 
fluorescence excitation wavelength maxima (λemission 651 nm); λem: the fluorescence emission 
wavelength maxima (λexcitaion 420 nm); τF: fluorescence lifetime; Φ�: singlet oxygen quantum 
yield. (
a
: distilled water; 
b
: methanol; 
c
: DMPC liposomal solution; 
d
: deuterated methanol). 
3.4. Cellular uptake of Tat-TPP in comparison with TPPS2a 
Human squamous cell carcinoma HN5 cells were incubated with the Tat-TPP conjugate or the 
amphiphilic sulfonated derivative, TPPS2a and cellular fluorescence levels were compared as a 
function of time or concentration. Control cells without applied drug exhibited negligible 
fluorescence levels. As shown in Fig. 4A, time-dependent cell uptake was found for both 
photosensitisers. Higher fluorescence levels were measured in cells treated with Tat-TPP (1 �M) 
compared to TPPS2a (1.3 �M) at longer incubation times even though the concentration of Tat-
TPP was slightly lower. The variation in cellular fluorescence versus concentration up to 5 �M 
recorded at 18 hr, the time-point used in subsequent PCI studies, shown in Fig. 4B. Above 1 �M, 
relatively little increase in fluorescence levels was observed. In addition, after 18hr incubation, the 
fluorescence intensity was measured to be three times higher in cells treated with 0.1 �M Tat-TPP, 
the concentration used in subsequent PCI studies, compared with TPPS2a using the same 
concentration. 
To study the uptake mechanism of Tat-TPP and the possible involvement of endocytosis, which is 
temperature-dependent unlike passive transport, experiments using low temperature incubation 
were performed. The cellular uptake of Tat-TPP exhibits a temperature dependence, as shown in 
Fig. 4C. Incubation at 4 ºC resulted in a significant reduction of cellular uptake compared to 
incubation at 37 ºC (p < 0.01). The same behaviour was also observed in the cells incubated with 
TPPS2a, which is known to be taken up via endocytosis [37]. 
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Fig. 4. Cellular fluorescence levels of Tat-TPP in comparison with TPPS2a in HN5 cells. A: Cells 
were incubated with Tat-TPP (1 �M) and TPPS2a (1.3 �M) for 8 hr. B: Cells were incubated with 
Tat-TPP (up to 5 �M) for 18hr. C: Normalised cellular fluorescence levels of Tat-TPP (1 �M) and 
TPPS2a (1.3 �M) at 4 ºC or 37 ºC after 1 hr incubation. 
3.5. Subcellular localisation and light-induced redistribution of Tat-TPP using confocal 
microscopy 
After 18hr incubation, a granular intracellular distribution of the Tat-TPP conjugate was observed 
by confocal microscopy (Fig. 5A), which became diffuse following prolonged light exposure (Fig. 
5B). The exposure time needed to acquire the images was small (< 10 s) compared with the 
duration of the light exposure required to induce the redistribution (10 min). A slight increase of 
about 20 % in integrated cellular fluorescence intensity accompanied the redistribution which we 
have also observed in similar experiments using aluminium disulfonated phthalocyanine and is 
believed to result from the reduction in concentration self-quenching of fluorescence [43]. 
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Fig. 5. Cellular distribution of Tat-TPP and the redistribution after irradiation on stage in HN5 
cells by confocal microscopy. A: before light; B: 10 min light exposure. Light source: 543 nm 
confocal microscope laser. Cells were incubated with 2.5 �M Tat-TPP for 18 hr. Scale bar: 20 �m. 
The subcelllular localisation of Tat-TPP (Fig. A and D) was investigated by co-labelling cells 
with LysoTracker Green (Fig. 6B) or MitoTracker Green (Fig. 6E), since a granular or punctate 
subcellular distribution can be associated with either lysosomal or mitochondrial uptake. As 
shown in the merged images Fig. 6C and 6F, most Tat-TPP was found co-localised with 
lysosomes (yellow). Less overlap was apparent using the mitochondrial probe. 
Fig. 6. Colocalisation studies of Tat-TPP versus LysoTracker Green or MitoTracker Green in 
HN5 cells by confocal microscopy. Cells were incubated 2.5 �M Tat-TPP for 18 hr. 50 nM of 
LysoTracker Green or MitoTracker Green was applied to cells 30 min before imaging. A and D: 
Tat-TPP; B: LysoTracker Green; C: merged A and B; E: MitoTracker Green; F: merged D and E. 
Scale bar: 20 �m. 
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3.6. Phototoxicity and the PCI effect of Tat-TPP combing saporin in HN5 cells 
The phototoxicity of the Tat-TPP conjugate in HN5 cells was studied as a function of both 
incubation concentration (up to 0.2 �M) and different light exposures (Fig. 7, black, dark and light 
blue lines). The phototoxicity induced by Tat-TPP was found to increase with both the light and 
drug dose. Cell viability was reduced to 40 % and 25 % using the conjugate at concentration of 
0.1 �M and 0.2 �M respectively after 3 min light exposure, which corresponds to a fluence of 1.3 
-2 
J cm Control values without light exposure are given by the ordinate readings, which show that 
little dark toxicity was evident induced by the conjugate. Controls performed with light only 
showed no measureable reduction in viability. 
Previous studies have shown that a sub-lethal combination of photosensitiser and light dose, 
corresponding to c. 50 % reduction in viability, is the optimal condition for PCI treatment [35,37]. 
The PCI effect in combination with saporin was therefore examined using a concentration of 0.1 
�M and 3 minutes light exposure for the Tat-TPP conjugate. In Fig. 7, the solid purple and orange 
lines represent the cell viability after being treated with increasing doses of saporin alone (10 and 
25 nM). Control values for saporin only without light exposure are given by the ordinate readings. 
After light exposure there was no significant enhancement in toxicity with saporin only, and the 
viability at the 3 min timepoint was measured as 56% for 10 nM saporin. However, significantly 
enhanced cell killing (p < 0.001) was demonstrated by PCI using Tat-TPP in combination with 
saporin at each dose (dotted lines), and for 10 nM the viability was reduced to 5%. In summary, 
using 10 nM saporin and 0.1 �M Tat-TPP, PCI treatment significantly reduced the cell viability by 
factors of 11.2 and 7.3 compared to saporin and Tat-TPP alone respectively after 3 min light 
exposure. PCI using the Tat-TPP conjugate therefore significantly enhanced the cytotoxicity 
induced by the type I RIP toxin, saporin. 
Fig. 7. Tat-TPP PDT (without saporin) and PCI effect (with saporin) in HN5 cells. Cells were 
incubated with 0.1 �M or 0.2 �M Tat-TPP, with or without saporin (10, 25 nM) for 18hr. 
Irradiation was carried out up to 5 min using a blue lamp. Cell viability was examined by the 
MTT assay 48 hr after exposure to light. 
4. Discussion 
In this study a cell penetrating peptide containing the core Tat sequence conjugated to a 
porphyrin (TPP) photosensitiser was investigated for photochemical internalisation (PCI), which 
is a site-specific technique for improving drug delivery. The key property required of a 
photosensitiser designed for PCI is the ability to localise specifically in endo/lysosomal 
membranes This is a key difference from photosensitisers designed for photodynamic therapy 
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where localisation in other subcellular compartments may confer an advantage (e.g. in 
mitochondria) rather than the specific endo/lysosomal localisation required for PCI. The efficacy 
of the water soluble peptide-porphyrin bioconjugate for PCI was investigated in a human head and 
neck squamous cell carcinoma cell line, which was selected on the basis that PCI may be suited to 
head and neck cancer therapy. Prior to the cellular studies, a series of spectroscopic and 
photophysical studies of the conjugate were carried out in different solvents, including a 
liposomal solution, to investigate its physicochemical properties. The Tat-TPP conjugate 
displayed typical fluorescence spectra in aqueous solution for a tetraphenyl porphyrin with two 
emission bands, but a red shift was observed in aqueous solution containing DMPC liposomes in 
both excitation and emission spectra (Fig. 3), which would be consistent with binding of the 
conjugate to the liposomal membrane. Such spectral shifts upon membrane binding of porphyrins 
have been reported in numerous studies [44,45]. This result would imply that the bioconjugate 
should also bind to cellular/organelle membranes, which is a key property required of 
photosensitisers used for PCI [46]. The fluorescence lifetime of Tat-TPP in methanol was 
measured as 8.7 ns compared to a value of 9.7 ns for TPPS4 which is in good agreement with the 
result from another study [47]. The singlet oxygen yield of the Tat-TPP conjugate was determined 
in methanol, giving Φ� = 0.54, which is close to a reported value of 0.56 for TPP [46], . 
The cellular uptake of the Tat-TPP conjugate was investigated in the HN5 human 
squamous cell carcinoma line in comparison to TPPS2a which is an amphiphilic tetraphenyl 
porphyrin used for both PCI and PDT. The results in Fig. 4A show that the conjugate was taken 
up by cells efficiently with fluorescence levels comparable to those using a similar concentration 
of TPPS2a. Incubation at 4ºC reduced the uptake of both photosensitisers, although to a lesser 
extent with the conjugate, which is consistent with the involvement of an energy-dependent 
endocytic mechanism of cellular uptake (Fig. 4C). The residual uptake of the conjugate at 
conjugate may be due to binding of the cationic Tat peptide to the cell membrane as previously 
proposed [46]. The subcellular distribution of the Tat-TPP conjugate was observed to be similar 
to TPPS2a (data not shown) exhibiting a granular pattern which became diffuse after light 
exposure (Fig. 5), which is consistent with the endo/lysosomal rupture mechanism required for 
PCI. Co-localisation studies with lysosomal and mitochondria probes showed that the conjugate 
appears to accumulate mainly in lysosomes as a consequence of endocytic cellular uptake. Since 
the molecular weight of the Tat conjugate is approx. 4000 Da, endocytic uptake would be 
expected for a molecule of this size. Overall, the results indicate that endocytosis is the main 
uptake mechanism of Tat-porphyrin conjugates, and that the conjugate is likely to be bound to the 
endo/lysosomal membrane instead of the aqueous lysosomal compartment based on the 
observation of membrane binding in the liposome studies. In a previous study, we investigated the 
photoinduced membrane permeation by the same Tat-porphyrin conjugate in relation to their 
antibacterial PDT effects [30]. Photo-induced release of carboxyfluorescein entrapped within 
unilamellar vesicles prepared from negatively charged lipids was observed, which mirrors the 
light-induced intracellular redistribution observed in the present study. Collectively, the 
experimental results presented here are in agreement with results of Vicente and co-workers that 
Tat-porphyrin conjugates are taken up efficiently by cells and can display an endo/lysosomal 
intracellular localisation [29,48,49]. Moreover, in another study it was found cationic porphyrins 
without the peptide component exhibited preferential mitochondrial uptake, which renders them 
unsuitable for PCI [49]. The serum stability of peptide-porphyrin conjugates [48] has also been 
investigated and it was found that these conjugates can undergo partially hydrolysis by proteolytic 
enzymes after 24 hr incubation. It is possible that the conjugate used here may undergo similar 
processes, although this should have no effect upon the efficiency of subsequent photoinduced 
membrane damage, and further studies need to be carried out on the optimum incubation time. 
The choice of the 18 hr incubation time used here was based on previous PCI studies with other 
porphyrin photosensitisers. 
To test whether the Tat-TPP conjugate has the potential for PCI, its phototoxicity was 
examined in the HN5 line in combination with the macromolecular toxin, saporin, As shown in 
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Fig. 7, Tat-TPP induced phototoxicity using low concentrations, and a sub-lethal combination of 
photosensitiser and light dose suitable for PCI was identified. The significantly enhanced cell 
killing achieved by combing low concentrations of saporin with a sub-lethal light dose 
demonstrated that the Tat-TPP conjugate is capable of acting as a PCI photosensitiser, since the 
same concentrations of saporin used without illumination are non-toxic. The PCI effect using Tat-
TPP was found to be comparable to another PCI photosensitiser TPPS2a in which the combination 
of sub-lethal PDT and saporin treatment induced 95 % reduction of cell viability [35,36]. The 
concentration employed here for the Tat-TPP conjugate of 0.1 �M is comparable to 
concentrations employed for PCI with TPPS2a. However since we observed higher cellular 
fluorescence levels using the conjugate than TPPS2a (section 3.4), future studies may therefore be 
able to employ even lower concentrations of the conjugate. 
The present study is the first attempt to incorporate the cell penetrating peptide­
photosensitiser conjugation strategy for PCI-enhanced delivery of a macromolecular toxin. The 
growing number of cell penetrating peptides that are becoming available [4,50] together with 
efforts to incorporate tumour targeting, add to the versatility of this approach. In summary, it has 
been demonstrated that a CPP-photosensitiser conjugate exhibits favourable properties for PCI. 
Firstly, the combination of good photophysical properties, water solubility yet sufficient 
amphiphilicity to localise in membranes. Secondly, efficient cellular uptake and low dark toxicity, 
and finally the synergistic PCI cytotoxicity in combination with saporin. A further advantage is 
that conjugation to a CPP allows photosensitisers like TPPs, with good photophysical properties 
to be used, whereas on their own they are not suitable for PCI applications since they are water-
insoluble, and not amphiphilic. Not surprisingly, some studies have pointed out that Tat peptide 
bioconjugates might result differently in vitro and in vivo [51,52], therefore future in vivo studies 
need to carefully consider the differences in experimental settings. Although limited cell 
specificity has been a drawback in the use of CPPs such as the Tat sequence [53], although this 
may improve in future, PCI selectivity can also be achieved through its light-activated site 
specificity so that the therapeutic effects are confined to the area exposed to light. 
Acknowledgements 
This study was supported in part by grants from Biotechnology and Biological Sciences Research 
Council grants BBD0127831 (IM Eggleston), and BBD0113291 (M Wilson, AJ MacRobert). We 
are grateful for assistance from Dr Ludovic Bourré in the preparation of the liposomes. 
Figure captions: 
Fig. 1. Structures of modified tetraphenylporphyrin 1 and Tat-tetraphenylporphyrin (Tat-TPP) 
bioconjugate 2. 
Fig. 2. Absorption spectrum of 5 �M Tat-TPP conjugate in aqueous solution. Inset: the Q band 
region from 450 nm to 700 nm. 
Fig. 3. Fluorescence spectrum of 2.5 �M Tat-TPP in aqueous and DMPC liposomal solutions. A: 
Emission spectra (λexcitation 420 nm); B: Excitation spectra (λemission 651 nm). The emission spectra 
were corrected for the variation of detector sensitivity with wavelength. Front surface 
excitation/detection geometry was employed to minimise self-absorption. 
Fig. 4. Cellular fluorescence levels of Tat-TPP in comparison with TPPS2a in HN5 cells. A: Cells 
were incubated with Tat-TPP (1 �M) and TPPS2a (1.3 �M) for 8 hr. B: Cells were incubated with 
Tat-TPP (up to 5 �M) for 18hr. C: Normalised cellular fluorescence levels of Tat-TPP (1 �M) and 
TPPS2a (1.3 �M) at 4 ºC or 37 ºC after 1 hr incubation. 
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Fig. 5. Cellular distribution of Tat-TPP and the redistribution after irradiation on stage in HN5 
cells by confocal microscopy. A: before light; B: 10 min light exposure. Light source: 543nm 
confocal microscope laser. Cells were incubated with 2.5�M Tat-TPP for 18 hr. Scale bar: 20 �m. 
Fig. 6. Colocalisation studies of Tat-TPP versus LysoTracker Green or MitoTracker Green in 
HN5 cells by confocal microscopy. Cells were incubated 2.5�M Tat-TPP for 18hr. 50 nM of 
LysoTracker Green or MitoTracker Green was applied to cells 30 min before imaging. A and D: 
Tat-TPP; B: LysoTracker Green; C: merged A and B; E: MitoTracker Green; F: merged D and E. 
Scale bar: 20 �m. 
Fig. 7. Tat-TPP PDT (without saporin) and PCI effect (with saporin) in HN5 cells. Cells were 
incubated with 0.1 �M or 0.2 �M Tat-TPP, with or without saporin (10, 25 nM) for 18hr. 
Irradiation was carried out up to 5 min using a blue lamp. Cell viability was examined by the 
MTT assay 48 hr after exposure to light. 
Table captions: 
Table 1 A summary of the photophysical properties of the Tat-TPP conjugate. λabs Soret: the peak 
Soret band absorption; λabs Q: the peak Q band absorption in the red spectral region; λex: the 
fluorescence excitation wavelength maxima (λemission 651 nm); λem: the fluorescence emission 
wavelength maxima (λexcitaion 420 nm); τF: fluorescence lifetime; Φ�: singlet oxygen quantum 
yield. (
a
: distilled water; 
b
: methanol; 
c
: DMPC liposomal solution; 
d
: deuterated methanol). 
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Table 1 
b ddH2O
a 
MeOH DMPC
c 
MeOD
418 414 -λabs Soret (nm) -
λabs Q (nm) 642 645 - ­
λex (nm) 417 - 420 ­
λem (nm) 652, 714 - 655, 721 ­
τF (ns) - 8.7 - 10.7 
- - - 0.54Φ� 
Table 1 A summary of the photophysical properties of the Tat-TPP conjugate. λabs 
Soret: the peak Soret band absorption; λabs Q: the peak Q band absorption in the red 
spectral region; λex: the fluorescence excitation wavelength maxima (λemission 651nm); 
λem: the fluorescence emission wavelength maxima (λexcitaion 420nm); τF: fluorescence 
lifetime; Φ�: singlet oxygen quantum yield. (
a
: distilled water; 
b
: methanol; 
c
: DMPC 
d
liposomal solution; : deuterated methanol). 
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